Cerebrovascular events in renal transplant recipients

Transplantation

Volumn 87, Issue 1, 2009, Pages 112-117

  Abedini, Sadollah ^a,g   Holme, Ingar ^b   Fellström, Bengt ^c   Jardine, Alan ^d   Cole, Edward ^e   Maes, Bart ^f   Holdaas, Hallvard ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d WESTERN INFIRMARY   (United Kingdom)

^e TORONTO GENERAL HOSPITAL   (Canada)

^f Heilig Hartziekenhuis   (Belgium)

^g Toensberg County Hospital   (Norway)

Author keywords

Cerebrovascular disease; Diabetes mellitus; Hypertension; Renal transplantation; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; COUMARIN; CREATININE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRATE; PLACEBO; PREDNISOLONE; VITAMIN D; WARFARIN; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; CEREBROVASCULAR DISEASE; PATHOLOGY;

CEREBROVASCULAR DISORDERS; FATTY ACIDS, MONOUNSATURATED; HUMANS; INDOLES; KIDNEY TRANSPLANTATION; RISK FACTORS;

EID: 58949092525     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31818bfce8     Document Type: Article

References (27)

1. Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 1999; 14: 648.
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112.
3. Holdaas H, Fellstrom B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT extension study. Am J Transplant 2005; 5: 2929.
4. Jardine AG, Holdaas H, Fellstrom B, et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: Post-hoc subgroup analyses of the ALERT Study. Am J Transplant 2004; 4: 988.
5. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735.
6. Soveri I, Holdaas H, Jardine A, et al. Renal transplant dysfunction - Importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality. Nephrol Dial Transplant 2006; 21: 2282.
7. Howard RJ, Patton PR, Reed AI, et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002; 73: 1923.
8. Aull-Watschinger S, Konstantin H, Demetriou D, et al. Pre-transplant predictors of cerebrovascular events after kidney transplantation. Nephrol Dial Transplant 2008; 23: 1429.
9. PonticelliC,Campise MR. Neurological complicationsin kidney transplant recipients. J Nephrol 2005; 18: 521.
10. de Mattos AM, Prather J, Olyaei AJ, et al. Cardiovascular events following renal transplantation: Role of traditional and transplant-specific risk factors. Kidney Int 2006; 70: 757.
11. Wijdicks EF, Torres VE, Schievink WI, et al. Cerebral hemorrhage in recipients of renal transplantation. Mayo Clin Proc 1999; 74: 1111.
12. Oliveras A, Roquer J, Puig JM, et al. Stroke in renal transplant recipients: Epidemiology, predictive risk factors and outcome. Clin Transplant 2003; 17: 1.
13. Adams HP Jr, Dawson G, Coffman TJ, et al. Stroke in renal transplant recipients. Arch Neurol 1986; 43: 113.
14. Holdaas H, Fellstrom B, Holme I, et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. J Cardiovasc Risk 2001; 8: 63.
15. Tirschwell DL, Smith NL, Heckbert SR, et al. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 2004; 63: 1868.
16. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024.
17. Kent DM. Stroke - An equal opportunity for the initiation of statin therapy. N Engl J Med 2006; 355: 613.
18. Seliger SL, Gillen DL, TirschwellD,et al. Risk factors for incident stroke among patients with end-stage renal disease. J Am Soc Nephrol 2003; 14: 2623.
19. Abramson JL, Jurkovitz CT, Vaccarino V, et al. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: The ARIC Study. Kidney Int 2003; 64: 610.
20. Hjelmesaeth J, Hartmann A, Leivestad T, et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006; 69: 588.
21. Chauveau D, Pirson Y, Verellen-Dumoulin C, et al. Intracranial aneu-rysms in autosomal dominant polycystic kidney disease. Kidney Int 1994; 45: 1140.
22. Yamada Y, Metoki N, Yoshida H, et al. Genetic risk for ischemic and hemorrhagic stroke. Arterioscler Thromb Vasc Biol 2006; 26: 1920.
23. Nakayama M, MetokiH,TerawakiH, et al. Kidney dysfunctionasarisk factor for first symptomatic stroke events in a general Japanese population - The Ohasama study. Nephrol Dial Transplant 2007; 22: 1910.
24. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular diseasein hemodialysis patients: The USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005; 16: 1788.
25. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238.
26. Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular diseaseorother high-risk conditions. Lancet 2004; 363: 757.
27. Amarenco P, Bogousslavsky J, Callahan A III, et al. High-dose atorva-statin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549.